Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025)
Monopar Therapeutics' (MNPR) quarterly Cash from Financing Activities came in at -$384680.0 in Q4 2025, down 100.69% year-on-year from $56.1 million in Q4 2024, and down 100.42% quarter-over-quarter from $92.4 million in Q3 2025.
Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Cash from Financing Activities across 9 years of filings, most recently posting -$384680.0 for Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at -$384680.0, down 100.69% year-over-year; the trailing twelve-month figure through Dec 2025 was $91.6 million (up 54.45% YoY), and the FY2025 annual result was $91.6 million, up 54.45% from the prior year.
- Cash from Financing Activities came in at -$384680.0 for Q4 2025 at Monopar Therapeutics, down from $92.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $92.4 million in Q3 2025 to a low of -$384680.0 in Q4 2025.
- The 5-year median for Cash from Financing Activities is -$8845.5 (2021), against an average of $8.2 million.
- Peak annual rise in Cash from Financing Activities reached 558897.68% in 2025, while the deepest fall reached 3094.32% in 2025.
- Monopar Therapeutics' Cash from Financing Activities stood at -$7772.0 in 2021, then jumped by 1885.09% to $138737.0 in 2022, then surged by 141.14% to $334548.0 in 2023, then surged by 16679.9% to $56.1 million in 2024, then slumped by 100.69% to -$384680.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$384680.0 (Q4 2025), $92.4 million (Q3 2025), and -$316845.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 85,464.43 |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - | -384,680.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -384,680.00 |
| Dec 31, 2025 | -384,680.00 |
| Sep 30, 2025 | 92.39 Mn |
| Sep 30, 2025 | 92.39 Mn |
| Jun 30, 2025 | -316,845.00 |
| Jun 30, 2025 | -316,845.00 |
| Mar 31, 2025 | -115,682.00 |
| Mar 31, 2025 | -115,682.00 |
| Dec 31, 2024 | 56.14 Mn |
| Dec 31, 2024 | 56.14 Mn |
| Sep 30, 2024 | -16,534.00 |
| Sep 30, 2024 | -16,534.00 |
| Jun 30, 2024 | -9,919.00 |
| Jun 30, 2024 | -9,919.00 |
| Mar 31, 2024 | 3.18 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 334,548.00 |
| Dec 31, 2023 | 334,548.00 |
| Sep 30, 2023 | 246,703.00 |
| Sep 30, 2023 | 246,703.00 |